Citadel Advisors’s Acumen Pharmaceuticals ABOS Stock Holding History

Citadel Advisors’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$28.3K	Buy	+12,000	New	+$30.6K	﹤0.01%	12588
2025 Q2	–	Sell	-27,500	Closed	-$30.3K	–	12309
2025 Q1	$30.3K	Sell	27,500 -15,800	-36%	-$22.6K	﹤0.01%	12817
2024 Q4	$74.5K	Sell	43,300 -6,200	-13%	-$14.9K	﹤0.01%	11874
2024 Q3	$123K	Buy	49,500 +17,000	+52%	+$46.1K	﹤0.01%	10841
2024 Q2	$78.7K	Buy	32,500 +22,900	+239%	+$72.9K	﹤0.01%	11235
2024 Q1	$38.9K	Sell	9,600 -3,200	-25%	-$12.1K	﹤0.01%	12420
2023 Q4	$49.2K	Sell	12,800 -2,400	-16%	-$7.12K	﹤0.01%	11795
2023 Q3	$63.1K	Sell	15,200 -3,700	-20%	-$22.9K	﹤0.01%	11460
2023 Q2	$90.9K	Buy	+18,900	New	+$90.5K	﹤0.01%	11071
2023 Q1	–	Sell	-700	Closed	-$3.78K	–	14628
2022 Q4	$3.78K	Buy	+700	New	+$4.7K	﹤0.01%	14171
2022 Q2	–	Sell	-20,000	Closed	-$78K	–	12756
2022 Q1	$78K	Buy	+20,000	New	+$109K	﹤0.01%	12490

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Citadel Advisors's ABOS Position: Q1 2026 in Review

Citadel Advisors sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 345,283 shares — an estimated $881K sold.

Citadel Advisors first reported a position in ABOS in Q3 2021 and held it in 14 quarters. The position peaked at $845K in Q3 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

Citadel Advisors reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Citadel Advisors sold 345,283 Acumen Pharmaceuticals shares in Q1 2026, an estimated $881K.
Citadel Advisors first reported a position in Acumen Pharmaceuticals in Q3 2021 and held it in 14 quarters.
Citadel Advisors's Acumen Pharmaceuticals position peaked at $845K in Q3 2025.
84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.